Skip to main content

Table 2 Subgroup analysis of the association between MTHFR A1298C polymorphism and CHD

From: MTHFR A1298C polymorphisms reduce the risk of congenital heart defects: a meta-analysis from 16 case-control studies

Subgroup analysis Genetic model
C vs. A CC vs. AA CC vs. AC AC vs. AA Dominant model Recessive model
No. OR 95% CI No. OR 95% CI No. OR 95% CI No. OR 95% CI No. OR 95% CI No. OR 95% CI
Summary 16 1.13 0.92–1.37 15 1.33 0.92–1.92 15 1.25 0.98–1.60 16 1.05 0.81–1.36 16 1.10 0.84–1.43 15 1.38 1.10–1.73
HWE
 Consistent 12 1.02 0.85–1.21 11 1.02 0.73–1.42 11 1.14 0.85–1.52 12 1.00 0.78–1.28 12 1.00 0.79–1.28 11 1.10 0.83–1.44
 Inconsistent 4 1.55 0.94–2.57 4 2.97 1.89–4.66 4 1.59 1.01–2.50 4 1.11 0.40–3.06 4 1.37 0.56–3.36 4 2.21 1.49–3.27
Down’s syndrome
 Without 14 1.20 0.98–1.47 13 1.47 1.01–2.14 13 1.29 1.00–1.66 14 1.14 0.86–1.50 14 1.19 0.90–1.57 13 1.44 1.14–1.82
 With 2 0.69 0.48–0.98 2 0.50 0.19–1.31 2 0.86 0.33–2.23 2 0.59 0.36–0.95 2 0.57 0.36–0.92 2 0.66 0.26–1.68
Region
 Europe 6 1.06 0.81–1.40 6 1.36 0.85–2.17 6 1.48 1.05–2.09 6 0.91 0.62–1.35 6 0.98 0.66–1.46 6 1.40 1.01–1.94
 Asia 6 1.27 0.87–1.85 5 1.44 0.67–3.13 5 1.06 0.68–1.66 6 1.27 0.79–2.04 6 1.28 0.80–2.05 5 1.42 0.95–2.14
 America 3 0.81 0.55–1.21 3 0.62 0.26–1.50 3 0.78 0.37–1.65 3 0.82 0.49–1.36 3 0.78 0.45–1.34 3 0.72 0.35–1.49
Sample size
 Large (>100) 9 1.05 0.90–1.22 8 1.10 0.82–1.49 8 1.30 0.96–1.77 9 1.01 0.80–1.28 9 1.03 0.83–1.28 8 1.21 0.91–1.62
 Small (<100) 7 1.13 0.69–1.87 7 1.60 0.74–3.45 7 1.17 0.78–1.76 7 1.02 0.51–2.05 7 1.09 0.54–2.21 7 1.68 1.17–2.41